Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.17+0.51 (+19.17%)
Close on Nov 18, 2026Market cap $117.87MP/E –Yield –
Armata Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Armata Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$40.70M. For fiscal 2025 it was -$36.63M. The highest annual figure on record is -$10.23M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.63M | – |
| FY2024 | Dec 31, 2024 | -$42.44M | – |
| FY2023 | Dec 31, 2023 | -$40.89M | – |
| FY2022 | Dec 31, 2022 | -$36.95M | – |
| FY2021 | Dec 31, 2021 | -$23.82M | – |
| FY2020 | Dec 31, 2020 | -$21.59M | – |
| FY2019 | Dec 31, 2019 | -$19.75M | – |
| FY2018 | Dec 31, 2018 | -$17.66M | – |
| FY2017 | Dec 31, 2017 | -$16.16M | – |
| FY2016 | Dec 31, 2016 | -$23.38M | – |
| FY2015 | Dec 31, 2015 | -$10.23M | – |
| FY2014 | Dec 31, 2014 | -$14.11M | – |
| FY2013 | Dec 31, 2013 | -$12.38M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.82M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.54M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.44M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.38M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.78M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.44M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.79M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.84M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.06M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$746.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.69M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.86M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.41M | – |
See a number that looks wrong?